ציין מניה או מטבע קריפטוגרפי בשורת החיפוש כדי לקבל סיכום
China Medical System Holdings Ltd
0867China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis. The company also offers Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; ILUMETRI, a tildrakizumab injection to treat moderate-tosevere plaque psoriasis; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. In addition, it provides Aethoxysklerol for sclerotherapy of different varicose veins; Heling Soothing product for skin soothing; Vmonalisa for mid to deep dermal implantation; Neauvia Hyaluronic Acid series; EyeOP1 to treat glaucoma; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; MOVICOL for treating chronic constipation and faecal impaction; and MeteoSpasmyl to treat gastrointestinal flatulence and pain. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited. Address: Island Place Tower, North Point, Hong Kong
Analytics
מחיר יעד של וול סטריט
93.89 HKDיחס רווח למחיר
12.3387תשואת דיבידנד
3.28 %השנה הנוכחית
שנה שעברה
רבעון נוכחי
רבע אחרון
השנה הנוכחית
שנה שעברה
רבעון נוכחי
רבע אחרון
דמויות מפתח 0867
ניתוח דיבידנדים 0867
גידול דיבידנד במשך 5 שנים
77 %צמיחה מתמשכת
3 שניםיחס תשלום ממוצע של 5 שנים
47 %היסטוריית דיבידנדים 0867
שווי מניות 0867
פיננסיים 0867
תוצאות | 2019 | דינמיקה |